Clinical Trial Update: HER2-positive Locally Advanced/Metastatic Gastric and/or Gastroesophageal Junction (GEJ) Adenocarcinoma in Russia

View source ↗

Summary

AstraZeneca's clinical trial in Russia evaluating HER2-positive gastric and gastroesophageal junction adenocarcinoma has completed (NCT05892926) and focuses on …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Cancer

Snippet

Sponsor: AstraZeneca | Conditions: Adenocarcinoma | Status: COMPLETED